Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy CEL-SCI stock
Learn how to easily invest in CEL-SCI stock.
CEL-SCI Corp is a biotechnology business based in the US. CEL-SCI shares (CVM) are listed on the NYSE MKT and all prices are listed in US Dollars.
How to buy shares in CEL-SCI
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CVM – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
CEL-SCI stock price (NYSE MKT: CVM)Use our graph to track the performance of CVM stocks over time.
CEL-SCI shares at a glance
|Latest market close||$4.17|
|52-week range||$2.49 - $12.90|
|50-day moving average||$3.45|
|200-day moving average||$6.69|
|Wall St. target price||$15.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.87|
Buy CEL-SCI shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy CEL-SCI stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
CEL-SCI price performance over time
|1 week (2022-06-30)||-7.33%|
|1 month (2022-06-03)||N/A|
|3 months (2022-04-07)||11.80%|
|6 months (2022-01-06)||-38.95%|
|1 year (2021-07-07)||-51.96%|
|2 years (2020-07-07)||-69.74%|
|3 years (2019-07-05)||8.42|
|5 years (2017-07-06)||75.95%|
|Gross profit TTM||$-23,108,897|
|Return on assets TTM||-41.46%|
|Return on equity TTM||-96.97%|
|Market capitalisation||$177.6 million|
TTM: trailing 12 months
CEL-SCI share dividends
We're not expecting CEL-SCI to pay a dividend over the next 12 months.
Have CEL-SCI's shares ever split?
CEL-SCI's shares were split on a 1:25 basis on 14 June 2017. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CEL-SCI shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for CEL-SCI shares which in turn could have impacted CEL-SCI's share price.
CEL-SCI share price volatility
Over the last 12 months, CEL-SCI's shares have ranged in value from as little as $2.49 up to $12.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while CEL-SCI's is 2.1561. This would suggest that CEL-SCI's shares are significantly more volatile than the average for this exchange and represent a higher risk.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia. .
CEL-SCI in the news
CEL-SCI Corporation to Present at LD Micro Invitational
CVM: ASCO 2022: The Details Matter
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
Frequently asked questionsWhat percentage of CEL-SCI is owned by insiders or institutions?
Currently 3.887% of CEL-SCI shares are held by insiders and 32.013% by institutions. When does the fiscal year end for CEL-SCI?
CEL-SCI's fiscal year ends in September. Where is CEL-SCI based?
CEL-SCI's address is: 8229 Boone Boulevard, Vienna, VA, United States, 22182 What is CEL-SCI's ISIN number?
CEL-SCI's international securities identification number is: US1508376076 What is CEL-SCI's CUSIP number?
CEL-SCI's Committee on Uniform Securities Identification Procedures number is: 150837409
More guides on Finder
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert